Defining and refining 5-HT receptor targets for migraine.

摘要

The triptans are well established as effective treatments for migraine, but the specific mechanisms responsible for their therapeutic effects remain unknown. Triptans selectively activate 5-HTj receptors, in particular the IB, ID, and IF receptor subtypes.1 There has been extensive discussion about which of these 5-HTj receptor subtypes are responsible for the therapeutic and adverse effects of treatment with triptans and about the locations in and around the brain where these effects might occur. In this issue of The Lancet Neurology, Farkkila and colleagues2 describe a clinical trial of an oral formulation of lasmiditan-a non-triptan selective 5-HT1F receptor agonist-as an acute treatment for migraine. This study, in combination with previous studies of the clinical pharmacology and efficacy of lasmiditan in migraine,34 confirms the potential of lasmiditan as a treatment for acute migraine and also provides new insights into the mechanisms of 5-HTj receptors in migraine.